GPT and metabolic dysfunction-associated steatotic liver disease: However, when given to patients with T2D and NAFLD for 24 weeks, dapagliflozin lowered circulating ALT, hepatic steatosis and fibrosis assessed by MRI-PDFF and magnetic resonance elastography (MRE) (334).